CHMP officially recommends Bavarian Nordic's vaccine for monkeypox in Europe

Bavarian Nordic’s vaccine was already approved in the monkeypox indication in the US and Canada – Imvanex is now one step closer to gaining the same authorization in Europe.

Photo: Bavarian Nordic / PR

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted Bavarian Nordic a positive opinion to extend smallpox vaccine Imvanex’s indication to include monkeypox, the firm reported Friday.

Now, the only thing standing in the way of the vaccine’s official use to ward off monkeypox in the region is the EU Commission, which has the final say in matters of drug authorization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs